Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025)
Inhibrx Biosciences (INBX) reported Other Non Operating Income of -$39000.0 for Q4 2025, down 165.0% year-over-year from $60000.0 in Q4 2024, and up 15.22% quarter-over-quarter from -$46000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Other Non Operating Income data on file, last reported at -$39000.0 in Q4 2025.
- Other Non Operating Income for Q4 2025 came in at -$39000.0, down 165.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$381000.0 (down 608.0% YoY), and the FY2025 annual result was -$381000.0, down 608.0% from the prior year.
- Other Non Operating Income rose to -$39000.0 in Q4 2025 per INBX's latest filing, from -$46000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $60000.0 in Q4 2024 and troughed at -$246000.0 in Q2 2025.
- A 3-year average of -$74181.8 and a median of -$50000.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income jumped 137.97% in 2024, then sank 845.45% in 2025.
- A 3-year view of Other Non Operating Income shows it stood at -$158000.0 in 2023, then jumped by 137.97% to $60000.0 in 2024, then slumped by 165.0% to -$39000.0 in 2025.
- Business Quant data shows INBX's Other Non Operating Income at -$39000.0 in Q4 2025, -$46000.0 in Q3 2025, and -$246000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Mar 31, 2025 | -50,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -217,000.00 |